U.S. Banks Stock News

In recent days, Digits announced an API partnership with BILL, enabling real-time syncing of bills, invoices, and payments into Digits’ Agentic General Ledger to streamline automated financial workflows for joint customers. At the same time, BILL is facing board turnover, activist pressure for cost cuts and strategic options, and heightened attention ahead of its upcoming earnings report. With BILL’s recent share price decline, we’ll explore how the new Digits integration shapes its...

Hubbell (HUBB) kicked off FY 2025 with third quarter revenue of US$1.5b and basic EPS of US$4.80, as net income excluding extra items reached US$255.1m. The company has seen quarterly revenue move from US$1.45b in Q2 2024 to US$1.48b in Q2 2025 and US$1.50b in Q3 2025. Over the same quarters, basic EPS tracked from US$4.04 to US$4.58 and then US$4.80. This sets the stage for investors to focus squarely on how these volumes and earnings are feeding through to margins and overall...

Recent move in Celldex Therapeutics Celldex Therapeutics (CLDX) has been on many watchlists after recent trading, with the stock closing at US$25.17. Short term and longer term returns have moved in different directions, prompting closer attention from investors. See our latest analysis for Celldex Therapeutics. The recent 1 day share price return of 2.07% comes after a weaker run over the past month, with a 30 day share price return of 6.81% and a year to date share price return of 6.81%...

HOKA, a brand under Deckers Outdoor (NYSE:DECK), has launched the Speedgoat 7 trail running shoe, paired with a global Vert Challenge for trail runners. The company has also introduced the Cielo X1 3.0, described as its lightest marathon racing shoe, alongside the "Speed of Light" campaign featuring trials and community events. These product releases and community initiatives mark fresh activity in Deckers' performance running category, beyond routine financial updates. Deckers Outdoor,...

This article walks you through the key numbers behind Paychex's current share price so you can judge for yourself how the market value compares with the underlying business. After reaching a last close of US$97.15, Paychex has seen a 7.4% decline over the past week, a 10.5% decline over both the past month and year to date, and a 32.3% decline over the past year, with a 3 year return of an 8.8% decline and a 5 year return of 23.5%. Recent attention on Paychex has centered on its role as a...

Farmers & Merchants Bancorp (FMCB) just closed out FY 2025 with fourth quarter revenue of US$61.9 million and basic EPS of US$34.80, while trailing twelve month revenue came in at US$239.3 million and EPS at US$135.00. Over the past few quarters, revenue has moved from US$53.5 million in Q4 2024 to US$57.9 million in Q1 2025, US$58.0 million in Q2, US$61.6 million in Q3, and US$61.9 million in Q4. Quarterly EPS stepped from US$31.17 to US$32.88, US$33.06, US$34.24, and US$34.80 over the same...

If you have been wondering whether Silicon Motion Technology is priced attractively right now, its recent share performance and current valuation metrics give you plenty to think about. The stock last closed at US$120.42, with returns of 3.6% over the past week, 28.4% over the last month, 28.4% year to date, 128.0% over one year, 94.9% over three years and 113.8% over five years. Recent coverage of Silicon Motion has focused on its position in the semiconductor space and the attention that...

If you are wondering whether Texas Instruments' current share price still offers value, looking at how the market is pricing its future cash flows and assets is a useful place to start. With the stock last closing at US$225.21 and returns of 14.5% over 7 days, 26.9% over 30 days, 26.9% year to date, 28.7% over 1 year, 34.3% over 3 years and 49.5% over 5 years, investors may be reassessing both its growth potential and risk profile. Recent attention on Texas Instruments has centered on its...

Recent industry research reported that the global automotive adhesives and sealants market is projected to reach about US$13.18 billion by 2035, supported by rising automobile production, growing electric vehicle adoption, and advances in high-strength, heat-resistant, and sustainable formulations. Huntsman is highlighted as a key participant in this expanding segment, with its newly launched high-performance structural adhesives tailored for electric vehicles positioning the company within...

If you are wondering whether MSCI's share price still makes sense after its recent run, you are not alone. The stock last closed at US$581.48, with returns of 2.9% over the past month, 0.8% over the past year, 7.4% over three years and 46.4% over five years. These figures may have shifted how some investors think about its risk and growth profile. Recent coverage has focused on MSCI as a key data and index provider for asset managers, ETFs and institutional investors, with attention on how...

Trustmark (TRMK) shares reacted to a packed January 27 update, as investors weighed better than expected adjusted earnings, record contributions from mortgage and wealth management, tighter cost control, and a higher quarterly dividend that lifted the annual payout rate. See our latest analysis for Trustmark. The earnings beat, dividend increase and recent buyback activity have come alongside a 30 day share price return of 10.90% and a 90 day share price return of 13.48%. The 1 year total...

Valvoline (NYSE:VVV) shareholders approved a new 2026 Omnibus Incentive Plan at the company’s Annual Meeting. Investors also elected new directors to the board, updating the company’s leadership and governance structure. Valvoline, traded on the NYSE under the ticker VVV, operates in automotive services and related products, serving drivers who need consistent, repeat maintenance and care for their vehicles. Governance changes such as a refreshed incentive plan and new directors sit...

If you are wondering whether Energizer Holdings is attractively priced right now, you are not alone. The stock has been drawing attention from investors trying to make sense of its current value. The share price closed at US$22.96 recently, with returns of 5.7% over the last 7 days and 15.2% over the last 30 days. However, the 1 year return of negative 26.5% and 5 year return of negative 40.6% present a tougher longer term picture. These mixed returns sit against a backdrop of ongoing...

Darling Ingredients, ticker NYSE:DAR, has experienced a sustained decline in revenue and profitability, with earnings per share weakening over the past three years. The continued drop in earnings highlights operational and market pressures that are now a central focus for investors tracking the company. These trends raise questions around how management will respond and what this could mean for the company’s longer term direction. Shares of Darling Ingredients last closed at $47.86, with...

If you are wondering whether YETI Holdings at around US$46.76 is a fair deal or not, this article will walk through what the current price might be saying about the stock's value. The share price has had mixed returns, with a 1.4% decline over the last week, a 4.3% gain over the past month and year to date, a 26.2% gain over the last year, and a 39.4% loss across five years, which can influence how investors think about both opportunity and risk. Recent attention around YETI has focused on...

If you are wondering whether Urban Edge Properties at around US$19.98 is still offering value or starting to look fully priced, you are asking the right question. The stock shows returns of 4.2% over 7 days, 4.6% over 30 days, 4.6% year to date, 4.3% over 1 year, 39.5% over 3 years and 59.3% over 5 years, which gives useful context before weighing up what you are paying today. Recent market attention has focused on Urban Edge Properties as a US real estate name, with investors weighing up...

Recently, Alkermes was highlighted with a Zacks Rank of #1 (Strong Buy), alongside a 9% upward revision in the Zacks Consensus Estimate for its full-year earnings over the past 90 days, signaling improving analyst expectations. This shift suggests growing confidence in Alkermes’ earnings profile within the Medical sector, as analysts reassess the company’s potential profit trajectory. Next, we’ll look at how this improved analyst sentiment and upgraded earnings outlook could shape Alkermes’...

Avidia Bancorp (AVBC) has wrapped up FY 2025 with fourth quarter revenue of US$26.1 million, net income of US$5.3 million and basic EPS of US$0.29, set against trailing twelve month revenue of US$82.1 million and a TTM net loss of US$3.3 million or EPS of US$0.18. The company has seen revenue move from US$88.5 million in FY 2024 to US$82.1 million on a trailing basis, while earnings have shifted from a profit of US$11.5 million over FY 2024 to a TTM loss of US$3.3 million. This leaves...

PepsiCo (PEP) has put fresh numbers on the board for FY 2025, reporting Q3 revenue of US$23.9b and basic EPS of US$1.90, alongside trailing 12 month revenue of US$92.4b and EPS of US$5.27. These figures sit against a reported net margin of 7.8% compared with 10.2% a year earlier. Over recent quarters the company has seen revenue range from US$17.9b in Q1 2025 to US$27.8b in Q4 2024, while basic EPS moved between US$0.92 and US$2.24. This gives investors a clear look at how headline growth has...

In late January 2026, MINISO Group Holding outlined an accelerated global growth roadmap at its Global Partner Conference in Guangzhou, focusing on immersive store upgrades, proprietary IP development, and expanded international reach, while also reporting a strong fiscal third quarter 2025 that exceeded its own revenue guidance and marked a milestone of more than 8,000 stores worldwide. An interesting development is the launch of the MINISO IP Genius Program, which aims to build...

Analyst reaction to Phase 1 trial progress Piper Sandler and Barclays recently updated their views on CytomX Therapeutics (CTMX) after promising Phase 1 data for varsetatug maseatecan in metastatic colorectal cancer, highlighting renewed investor attention ahead of further clinical readouts. See our latest analysis for CytomX Therapeutics. The share price, which last closed at US$6.07, has seen a 42.82% year to date share price return and a very large 1 year total shareholder return,...

BeOne Medicines (NasdaqGS:ONC) received its first regulatory clearance for BCL2 inhibitor sonrotoclax, supporting clinical development in chronic lymphocytic leukemia. The company extended its collaboration with InSysBio to apply translational modeling for dose selection and cytokine release syndrome risk management in future studies. BeOne Medicines focuses on oncology drug development. Sonrotoclax is now moving into a new regulatory phase that puts more attention on its BCL2 approach in...

AMETEK (AME) has just posted another set of quarterly numbers, with Q3 FY 2025 revenue at US$1,892.6 million and basic EPS of US$1.61 setting the tone for the year so far. The company has seen revenue move from US$1,708.6 million in Q3 FY 2024 to US$1,892.6 million in Q3 FY 2025. Over the same quarters, basic EPS went from US$1.47 to US$1.61, supported by trailing twelve month EPS of US$6.36 on revenue of about US$7.2 billion. Taken together with a trailing net margin of 20.5% versus 19.3% a...

Pfizer (PFE) has just posted its FY 2025 third quarter numbers, reporting revenue of US$16.7b and basic EPS of US$0.62, with trailing twelve month EPS at US$1.73. The company has seen revenue move from US$17.8b in Q4 2024 to US$13.7b in Q1 2025 and US$14.7b in Q2 2025, while quarterly EPS shifted from US$0.07 to US$0.52 and US$0.51 over the same stretch. This feeds into a 15.6% net profit margin over the last 12 months compared with 7.0% a year earlier, giving investors a clearer view of how...